secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001599298-24-000032
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics reports Q4 2023 GAAP net loss $36.6M; cash runway extended to Q1 2025 via $100M CEO note amendment
--------------------------------------------------------------------------------

- GAAP net loss Q4 2023 $36.6M ($0.05/sh) vs $19.3M ($0.07/sh) a year ago; full-year loss $614.9M primarily from $500M ivonescimab licensing fee.
- Cash and equivalents, restricted cash, and short-term investments $186.2M at Dec 31, 2023, down from $648.6M at Dec 31, 2022.
- Extended cash runway guidance to Q1 2025 from Q3 2024 after amending $100M CEO note to April 1, 2025 maturity with interest rate >12%.
- Actively enrolling two Phase III trials (HARMONi and HARMONi-3) for ivonescimab in NSCLC; HARMONi enrollment completion expected H2 2024.
- Updated Phase II data: 24-month OS rate 64.8% in 1L squamous NSCLC; median OS 22.5 months in 2L+ EGFR-mutant NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000032/0001599298-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000032/smmt-20240220.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer